Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Enrique Alvarez, Kavita V. Nair, Hiangkiat Tan, Kapil Rathi, Nicole B. Gabler, Eric M. Maiese, Chinmay Deshpande & Qiujun Shao. (2023) Real-world cost of care and site of care in patients with multiple sclerosis initiating infused disease-modifying therapies. Journal of Medical Economics 26:1, pages 494-502.
Read now
Read now
Surachat Ngorsuraches & Nabin Poudel. (2021) Incorporating patients’ preferences in the value assessment of disease-modifying therapies for multiple sclerosis: a narrative review. Expert Review of Pharmacoeconomics & Outcomes Research 21:2, pages 183-195.
Read now
Read now
Jacqueline Nicholas, Rachel Halpern, Marina Ziehn, Jesse Peterson-Brandt, Michael Leszko & Chinmay Deshpande. (2020) Real-world cost of treatment for multiple sclerosis patients initiating and receiving infused disease-modifying therapies per recommended label in the United States. Journal of Medical Economics 23:8, pages 885-893.
Read now
Read now
Emanuele D’Amico, Clara G Chisari, Lara Gitto, Aurora Zanghì, Simona Toscano & Francesco Patti. (2019) Pharmacoeconomics of synthetic therapies for multiple sclerosis. Expert Opinion on Pharmacotherapy 20:11, pages 1331-1340.
Read now
Read now
Saeed Taheri, Mohammad Ali Sahraian & Nazila Yousefi. (2019) Cost-effectiveness of alemtuzumab and natalizumab for relapsing-remitting multiple sclerosis treatment in Iran: decision analysis based on an indirect comparison. Journal of Medical Economics 22:1, pages 71-84.
Read now
Read now
Articles from other publishers (16)
Virender Bhan, Fraser Clift, Moogeh Baharnoori, Kimberly Thomas, Barkha P Patel, François Blanchette, Nicholas Adlard, Umakanth Vudumula, Kapil Gudala, Nikkita Dutta, Daniel Grima, Soukaïna Mouallif & Fatine Farhane. (2023) Cost–consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada. Journal of Comparative Effectiveness Research 12:9.
Crossref
Crossref
Paulo Martins, Björn Vandewalle, Jorge Félix, Carlos M. Capela, João J. Cerqueira, António V. Salgado, Diana G. Ferreira & Isabel Monteiro. (2022) Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal. PharmacoEconomics - Open 7:2, pages 229-241.
Crossref
Crossref
Y. Seitaridou, M. Dimitrova, T. Chamova, M. Kamusheva & P. Panayotov. (2022) Cost-Effectiveness of Multiple Sclerosis Therapies – A Literature Review. Acta Medica Bulgarica 49:4, pages 69-80.
Crossref
Crossref
Dominik Koeditz, Jürgen Frensch, Martin Bierbaum, Nils-Henning Ness, Benjamin Ettle & Tjalf Ziemssen. (2022) Evaluation der langfristigen klinischen und ökonomischen Auswirkungen einer Behandlung mit Ofatumumab gegenüber Dimethylfumarat und Glatirameracetat bei Patienten mit schubförmiger Multipler Sklerose aus gesellschaftlicher Sicht in Deutschland. Nervenheilkunde 41:07/08, pages 502-508.
Crossref
Crossref
Mahmoud A. AbdelRazek, Marcel Casasola, Roohallah Mollashahi, Alexander Brodski, Scott Morin, Aleksandra Augustynowicz, Sarmad Jassim, Marcelo Matiello & Jacob Sloane. (2022) Extended B-cell depletion beyond 6-months in patients receiving ocrelizumab or rituximab for CNS demyelinating disease. Multiple Sclerosis and Related Disorders 59, pages 103505.
Crossref
Crossref
Dominik Koeditz, Juergen Frensch, Martin Bierbaum, Nils-Henning Ness, Benjamin Ettle, Umakanth Vudumula, Kapil Gudala, Nicholas Adlard, Santosh Tiwari & Tjalf Ziemssen. (2022) Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany. Multiple Sclerosis Journal - Experimental, Translational and Clinical 8:1, pages 205521732210857.
Crossref
Crossref
Anggie Wiyani, Lohit Badgujar, Vivek Khurana & Nicholas Adlard. (2021) How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review. Neurology and Therapy 10:2, pages 557-583.
Crossref
Crossref
S. Simeonova & R. Nikolova. (2021) Significance of the Dominant Psychological and Physiological Aspects of the Occupational Stress Models. Acta Medica Bulgarica 48:4, pages 33-42.
Crossref
Crossref
Amanda Nash, Samira Aghlara-Fotovat, Andrea Hernandez, Christopher Scull & Omid Veiseh. (2021) Clinical translation of immunomodulatory therapeutics. Advanced Drug Delivery Reviews 176, pages 113896.
Crossref
Crossref
Daekwon Bae, Ji-Young Lee, Nina Ha, Jinsol Park, Jiyeon Baek, Donghyeon Suh, Hee Seon Lim, Soo Min Ko, Taehee Kim, Da Som Jeong & Woo-chan Son. (2021) CKD-506: A novel HDAC6-selective inhibitor that exerts therapeutic effects in a rodent model of multiple sclerosis. Scientific Reports 11:1.
Crossref
Crossref
V. Casado, I. Bonaventura, L. Brieva, S. Martínez-Yélamos, G. Martín, S. Presas-Rodriguez, M. Hervas, J.J. Hernández, E. Munteis, A. Escartin, L. Gubieras, M.A. Mañé-Martínez & L. Ramió-Torrentà. (2021) Direct costs of relapses in patients with relapsing-remitting multiple sclerosis. Neurology Perspectives 1:3, pages 160-169.
Crossref
Crossref
Viktor Chirikov, Ingrid Ma, Namita Joshi, Dipen Patel, Alden Smith, Cindy Giambrone, Noelle Cornelio & Lobat Hashemi. (2019) Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States. Value in Health 22:2, pages 168-176.
Crossref
Crossref
D. L. KlabukovaM. E. Holownia-VoloskovaM. V. DavydovskayaT. N. ErmolaevaK. I. PolyakovaA. G. FisunK. A. Kokushkin. (2018) Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review. PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology 11:3, pages 43-56.
Crossref
Crossref
Luis Hernandez, Malinda O’Donnell & Maarten Postma. (2018) Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations. PharmacoEconomics 36:10, pages 1223-1252.
Crossref
Crossref
Rosa C. Lucchetta, Fernanda S. Tonin, Helena H. L. Borba, Letícia P. Leonart, Vinicius L. Ferreira, Aline F. Bonetti, Bruno S. Riveros, Jefferson Becker, Roberto Pontarolo, Fernando Fernandez-Llimós & Astrid Wiens. (2018) Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: A Network Meta-Analysis. CNS Drugs 32:9, pages 813-826.
Crossref
Crossref
Nasrin Zahmatkeshan & Hamdollah Delaviz. (2017) Effect of Isometric Exercises on Ability and Balance of Patients With Multiple Sclerosis. Iranian Rehabilitation Journal 15:4, pages 415-420.
Crossref
Crossref